The head of Aspen Pharmacare Holdings Ltd. said South Africans may get access to Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro from next year in a coup for Africa’s biggest drug maker.

Aspen struck a 10-year, $41.5 million agreement with the US manufacturer that also includes other sub-Saharan African nations, giving it access to drugs including the diabetes shot whose sales globally are expected to surge in the coming years as it’s also approved for use in treating patients with obesity. The accord with Lilly can be extended by another decade, Chief Executive Officer Stephen Saad said Wednesday. …